Pharmafile Logo
Pharmafocus logo
Advanced Search

Eli Lilly

Showing 15 posts of 212 posts found.

Sanofi launches patent infringement lawsuit against Mylan over diabetes pen

October 25, 2017
Research and Development, Sales and Marketing Basaglar, Eli Lilly, Lantus, Mylan, Sanofi, diabetes, insulin, patent infringement, pharma

Sanofi has launched a lawsuit against Mylan as part of a dispute that alleges that the latter infringed upon 18 …

News
lilly2_web

Lilly looks to leave behind animal health business

October 25, 2017
Research and Development, Sales and Marketing Elanco, Eli Lilly, biotech, drugs, pharma, pharmaceutical

Eli Lilly released its Q3 financials and the major talking point was the announcement that the business was reviewing “strategic …

News
lilly_entrance_web

Lilly teams up with CureVac in $1.8 billion cancer vaccine partnership

October 19, 2017
Research and Development, Sales and Marketing Cancer, CureVac, Eli Lilly, Vaccine

Eli Lilly has announced it is to partner up with CureVac to leverage its proprietary RNActive technology in order to …

News
lilly_logo_2

Lilly reveals major senior leadership reshuffle

October 2, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, biotech, drugs, pharma, pharmaceutical

Eli Lilly revealed on 29 September that it would promote four staff members to senior staff positions, and two senior …

Appointment
lilly2_web

Lilly receives FDA breast cancer pill approval, doubts remain

September 29, 2017
Medical Communications, Sales and Marketing Eli Lilly, Verzenio, biotech, drugs, pharma, pharmaceutical

Eli Lilly has received an important approval for its breast cancer treatment, Verzenio. The drug will be the third to …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

September 15, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cosentyx, Eli Lilly, Martin Skreli, Teva, pharma, top ten

This week has been a particularly eventful one for the industry: among our top stories, Martin Shkreli finally heads to …

News

Lilly’s Cyramza combo boasts strong results in bladder cancer

September 11, 2017
Research and Development, Sales and Marketing Eli Lilly, bladder cancer, cyramza, immunotherapy, pharma

Eli Lilly has announced new Phase 3 data at the European Society for Medical Oncology 2017 Congress which further add …

News
gavel

Patently problematic? The impact of the Eli Lilly/Actavis intellectual property battle

September 4, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Eli Lilly, biotech, drugs, pemetrexed, pharma, pharmaceutical

The UK Supreme Court has sent shockwaves through the intellectual property world with its recent decision on Eli Lilly v …

Feature
lilly2_web

Lilly gets second shot at application for ‘blockbuster’ arthritis drug

August 31, 2017
Sales and Marketing Eli Lilly, arthritis, baricitinib, biotech, drugs, pharma, pharmaceutical

Earlier this year, Eli Lilly was on the receiving end of one of the most surprising setbacks in recent times …

News
novo_flag

Novo diabetes drug outperforms Lilly rival at Phase 3

August 17, 2017
Research and Development Eli Lilly, Novo Nordisk, diabetes, life sciences, medicine, pharma, pharmaceutical, type 2 diabetes

Novo Nordisk has revealed that its diabetes drug semaglutide managed to outperform Eli Lilly’s own treatment dulaglutide (Trulicity) in controlling …

News

Lilly snaps up autoimmune drug in $400m biotech partnership

July 25, 2017
Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, Nektar, aceutical, biotech, drugs, healthcare, phar, pharma

Eli Lilly is to enter a partnership with Nektar Therapeutics to tap into the biotech’s new autoimmune disease therapy as …

News

Eli Lilly arthritis drug outperforms Humira and receives NICE backing

June 30, 2017
Medical Communications, Research and Development, Sales and Marketing Eli Lilly, NICE, Olumiant, rheumatoid arthritis

Eli Lilly’s rheumatoid arthritis (RA) drug Olumiant (baricitinib) has been deemed cost-effective by NICE and has been recommended to be …

News
fda2outsideweb

FDA fast-tracks Pfizer and Lilly’s chronic pain drug

June 15, 2017
Research and Development, Sales and Marketing Eli Lilly, FDA, Pfizer

Pfizer and Eli Lilly are celebrating the FDA’s decision to grant fast-track designation to their joint venture tanezumab in the …

News

Lilly bolsters diabetes assets with $55m KeyBioscience deal

June 9, 2017
Medical Communications, Sales and Marketing Eli Lilly, KeyBiosciences

Eli Lilly has announced a strategic collaboration with KeyBioscience that sees the former company gain access to develop and commercialise …

News
sanofi_hq_reception_close

EMA’s CHMP recommends Sanofi’s Humalog biosimilar

May 22, 2017
Manufacturing and Production, Sales and Marketing Eli Lilly, Humalog, Sanofi

Sanofi has received a positive recommendation by the CHMP for its biosimilar to Eli Lilly’s Humalog. The recommendation for approval …

News

Latest content

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024

ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial

June 25, 2024

GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment

June 24, 2024